Urology
Volume 71, Issue 3 , Pages 390-394 , March 2008

Optimal Measure of PSA Kinetics to Identify Prostate Cancer

Received 31 March 2007 ,Accepted 19 October 2007.

References 

  1. Kirbly SR, Christmas TJ, Brawer MK. Prostate Cancer. 2nd edition. London, England: Mosby; 2001;
  2. Zhu H, Kimberly A, Roehl J, et al. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology. 2005;66:547–551
  3. Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol. 2003;169:445–457
  4. Benecchi L. Neuro-fuzzy system for prostate cancer diagnosis. Urology. 2006;68:357–361
  5. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215–2220
  6. Roobol MJ, Kranse R, De Koning HJ, et al. Prostate-specific antigen velocity at low prostate-specific antigens levels as screening tool for prostate cancer: results of second screening round of ERSPC. (Rotterdam) Urology. 2001;63:309–313
  7. Komatsu K, Wehner N, Prestigiacomo AF. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology. 1996;47:343–346
  8. Pound CR, Partin AW, Eisenberg MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  9. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441–1445
  10. D’Amico A, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specificity mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172:S42–S47
  11. Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis. 2006;9:169–172
  12. Choo R, Klotz L, Deboer G, et al. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int. 2004;94:295–298
  13. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–843
  14. Carter HB, Morrel CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Res. 1992;52:3323–3328
  15. Schmid HP, McNeal JE, Stamey TA. Observation on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031–2040
  16. Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum tu or marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999;45:1695–1707
  17. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441–1445
  18. Svatek RS, Shulman M, Choudhary PK, et al. Clinical analysis of prostate-specific antigen doubling time calculation methodology. Cancer. 2006;106:1047–1053
  19. Semjonow A, Hamm M, Rathert P. Half-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment?. Eur Urol. 1992;21:200–205
  20. Catalona WL Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–954
  21. Spurgeon SEF, Mongue-Tchokote S, Collins L, et al. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology. 2007;69:931–935
  22. Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, Section of Rotterdam. Urology. 2004;63:316–320
  23. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol. 2006;176:1392–1398

PII: S0090-4295(07)02271-6

doi: 10.1016/j.urology.2007.10.021

Urology
Volume 71, Issue 3 , Pages 390-394 , March 2008

Article Tools